Trovagene Enters into a Strategic Alliance with the Lurie Cancer Center and the Northwestern Medicine Developmental Therapeutics Institute
SAN DIEGO, CA and CHICAGO, IL –June 30, 2014 – Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.
The Lurie Cancer Center and NMDTI will work with Trovagene on clinical protocols that incorporate oncogene mutation monitoring during the course of cancer treatment and will assess the impact on overall disease management and patient outcomes. "The Lurie Cancer Center is focused on advancing personalized medicine through collaborations with leading developers of state-of-the-art genomic technologies, such as Trovagene, to facilitate clinical decision making and improve patient care," stated Leonidas C. Platanias, M.D., Ph.D., interim director of the Lurie Cancer Center. "We are excited about the increasing opportunities to tailor cancer treatment to the specific genetic abnormalities that drive disease, and as leading institutes focused on translational research, we are dedicated to the rapid integration of technologies that will make patient-specific therapy an affordable reality," said Francis J. Giles, M.D., associate director for Translational Medicine and Developmental Therapeutics at the Lurie Cancer Center and director of the NMDTI.
Trovagene is engaged in clinical collaborations with leading academic institutions and integrated healthcare networks to demonstrate the clinical utility of its precision cancer monitoring platform for the detection of oncogene mutations, and the assessment of tumor dynamics and treatment response over time. The Company is focused on expanding the clinical evidence to support broad market adoption of its molecular diagnostic platform and to generate health economic data necessary to establish favorable reimbursement. Trovagene’s precision cancer monitoring platform can detect cell-free DNA mutations in urine and provide physicians with a whole-body molecular view of the patient in order to determine mutational status, guide treatment selection, and to monitor disease progression over time.
"We look forward to working with the Lurie Cancer Center and NMDTI as Trovagene continues to expand the number of top healthcare institutions evaluating our precision cancer monitoring technology for implementation into the clinic," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Their world-class translational research organizations have a strong track record for bringing cutting-edge healthcare technologies to patients, and we are pleased that they are now among our clinical collaborators."
About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine Developmental Therapeutics Institute (NMDTI)
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University and NMDTI have launched a discipline-defining research program devoted to uniting and expanding their investment in the field of developmental therapeutics. This field creates a continuous synergistic loop linking preclinical basic science breakthroughs to the use of novel approaches to prevent cancer, to better predict its causes and behavior, and to develop better treatments for patients who suffer from cancer. Today, the Lurie Cancer Center is one of only 41 NCI-designated "Comprehensive" cancer centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 25 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer and part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities. The Lurie Cancer Center is affiliated with four leading teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children's Hospital of Chicago, the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran's Affairs Medical Center, treating more than 10,000 new cancer cases each year.
The Northwestern Medicine Developmental Therapeutics Institute (NMDTI) provides the infrastructure, expertise, and people to accelerate the developmental therapeutics process. With dedicated patient care facilities, experienced physician scientists, and specialized advanced practice providers, pharmacists, and allied staff, NMDTI brings a large external pipeline of investigational agents to our patients while accelerating the development of Northwestern University’s internal pipeline of novel therapies. The NMDTI Developmental Therapeutics Fellowship, supported by the Woman’s Board of Northwestern Memorial Hospital, focuses on nurturing physician scientists whose career is dedicated to curing cancer.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA and RNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.
David Moskowitz and Amy Caterina
Canale Communications, Inc.
Northwestern University Contact
Health Sciences Editor
(Last updated on June 30, 2014 )